Cytarabine

Generic Name
Cytarabine
Brand Names
Cytosar, Vyxeos
Drug Type
Small Molecule
Chemical Formula
C9H13N3O5
CAS Number
147-94-4
Unique Ingredient Identifier
04079A1RDZ
Background

A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)

Indication

For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.

Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.

Associated Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
Associated Therapies
-
Clinical Trials
Related News

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

First Posted Date
2003-10-07
Last Posted Date
2013-10-17
Lead Sponsor
Children's Oncology Group
Target Recruit Count
24
Registration Number
NCT00070187
Locations
🇺🇸

University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 60 locations

GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia

First Posted Date
2003-10-07
Last Posted Date
2013-06-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
51
Registration Number
NCT00070551
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

First Posted Date
2003-09-25
Last Posted Date
2013-12-04
Lead Sponsor
ALZA
Target Recruit Count
25
Registration Number
NCT00003827
Locations
🇺🇸

Cancer Center and Beckman Research Institute, City of Hope, Duarte, California, United States

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Relapsed Acute Lymphocytic Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-09-18
Last Posted Date
2013-07-10
Lead Sponsor
University of Nebraska
Target Recruit Count
30
Registration Number
NCT00002638
Locations
🇺🇸

University of Nebraska Medical Center, Omaha, Nebraska, United States

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
Interventions
Drug: ara-C
Biological: gemtuzumab ozogamicin
First Posted Date
2003-09-03
Last Posted Date
2016-07-14
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
60
Registration Number
NCT00006265
Locations
🇺🇸

CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C., Syracuse, New York, United States

🇺🇸

Veterans Affairs Medical Center - Dallas, Dallas, Texas, United States

🇺🇸

CCOP - Mount Sinai Medical Center, Miami Beach, Florida, United States

and more 75 locations

506U78 in Treating Patients With Refractory Hematologic Cancer

First Posted Date
2003-08-11
Last Posted Date
2013-07-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
148
Registration Number
NCT00002970
Locations
🇺🇸

Children's Oncology Group, Arcadia, California, United States

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Leukemia
First Posted Date
2003-08-07
Last Posted Date
2015-03-06
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
69
Registration Number
NCT00066794
Locations
🇺🇸

St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States

🇺🇸

Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States

🇺🇸

Munson Medical Center, Traverse City, Michigan, United States

and more 94 locations

Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

First Posted Date
2003-07-18
Last Posted Date
2018-11-07
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
60
Registration Number
NCT00065143
Locations
🇺🇸

The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

3-AP and Cytarabine in Treating Patients With Hematologic Cancer

First Posted Date
2003-07-09
Last Posted Date
2013-07-18
Lead Sponsor
Vion Pharmaceuticals
Registration Number
NCT00064090
Locations
🇺🇸

University of Texas - MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma

Phase 2
Completed
Conditions
Leukemia
Lymphoma
First Posted Date
2003-06-12
Last Posted Date
2012-02-20
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Registration Number
NCT00018954
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

🇪🇬

National Cancer Institute of Egypt, Cairo, Egypt

🇮🇳

Kidwai Memorial Institute of Oncology, Bangalore, India

and more 2 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy